Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus Medical's Beginning Cash Position for the quarter that ended in Jun. 2026 was R$2,874 Mil.
Globus Medical's quarterly Beginning Cash Position
increased
from Dec. 2025 (R$2,028 Mil) to Mar. 2026 (R$2,752 Mil) and
increased
from Mar. 2026 (R$2,752 Mil) to Jun. 2026 (R$2,874 Mil).
Globus Medical's annual Beginning Cash Position
increased
from Dec. 2023 (R$737 Mil) to Dec. 2024 (R$2,851 Mil) and
increased
from Dec. 2024 (R$2,851 Mil) to Dec. 2025 (R$4,280 Mil).
Globus Medical Beginning Cash Position Related Terms
Globus Medical Beginning Cash Position Historical Data
* Premium members only.
The historical data trend for Globus Medical's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Beginning Cash Position of R$2,874 Mil mean?
Globus Medical (BSP:G2ME34) has a Beginning Cash Position of R$2,874 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Globus Medical and its competitors.
Is Globus Medical's Beginning Cash Position too high?
Globus Medical's current Beginning Cash Position is R$2,874 Mil. Overall, Globus Medical has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's Beginning Cash Position compare to PODD and BRKR?
Globus Medical's Beginning Cash Position of R$2,874 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Globus Medical and its competitors. Globus Medical's current Beginning Cash Position is R$2,874 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (BSP:G2ME34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$58.52, compared to a current price of R$52.00 — trading 11.1% below its estimated fair value. The current Beginning Cash Position is R$2,874 Mil. Globus Medical's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Globus Medical (BSP:G2ME34), the current Beginning Cash Position is R$2,874 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (BSP:G2ME34) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of R$52.00 is trading 11.1% below its estimated GF Value™ of R$58.52.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for BSP:G2ME34:
Beginning Cash Position: R$2,874 Mil
GF Value™: R$58.52 vs. price of R$52.00 (11.1% below fair value)
No single metric tells the full story. See the BSP:G2ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
26GF Score
Get the complete analysis for BSP:G2ME34
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:G2ME34 has been successfully added to your 
